Alveolar macrophage inflammatory response

The alveolar macrophage inflammatory response is a coordinated physiological process involving the activation of resident lung macrophages in response to inhaled insults, such as pathogens or environmental toxins (Hussell & Bell, 2014). These cells act as sentinels, initiating the immune response by releasing a variety of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha) and various interleukins, which recruit other immune cells to the site of injury (Barnes, 2004). While this response is vital for host defense, its dysregulation is a hallmark of several chronic and acute pulmonary diseases, including chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) (Laskin et al., 2011). Pharmacological intervention typically targets the signaling pathways within these macrophages, such as the NF-kappaB or MAPK pathways, or the specific cytokines they produce (Giembycz, 2008). Common therapeutic agents include corticosteroids and phosphodiesterase-4 (PDE4) inhibitors, which aim to dampen the overactive inflammatory state to prevent tissue damage and preserve lung function (Rabe, 2011).

Other names

Alveolar macrophage activationPulmonary macrophage inflammationLung macrophage inflammatory response

Inhibition of pro-inflammatory cytokine production, suppression of NF-kappaB and MAPK signaling pathways, and modulation of oxidative stress responses within resident lung macrophages.